Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma
Background: Despite improvements in surgical methodologies and perioperative chemo- and radiotherapy, the prognosis for patients with esophageal and gastric cancer remains poor. Hence, there is a great need to identify complementary biomarkers for improved treatment stratification. Tumor-infiltratin...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-10-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2020.534761/full |
id |
doaj-bb05d56b6c934735a9d51b3acf1c2c2a |
---|---|
record_format |
Article |
spelling |
doaj-bb05d56b6c934735a9d51b3acf1c2c2a2020-11-25T03:52:47ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-10-011010.3389/fonc.2020.534761534761Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal AdenocarcinomaMartin Jeremiasen0Martin Jeremiasen1David Borg2David Borg3Charlotta Hedner4Maria Svensson5Björn Nodin6Karin Leandersson7Jan Johansson8Jan Johansson9Karin Jirström10Department of Clinical Sciences Lund, Surgery, Lund University, Lund, SwedenSkåne University Hospital, Lund, SwedenSkåne University Hospital, Lund, SwedenDepartment of Clinical Sciences Lund, Oncology and Therapeutic Pathology, Lund University, Lund, SwedenDepartment of Clinical Sciences Lund, Oncology and Therapeutic Pathology, Lund University, Lund, SwedenDepartment of Clinical Sciences Lund, Oncology and Therapeutic Pathology, Lund University, Lund, SwedenDepartment of Clinical Sciences Lund, Oncology and Therapeutic Pathology, Lund University, Lund, SwedenCancer Immunology, Department of Translational Medicine, Lund University, Malmö, SwedenDepartment of Clinical Sciences Lund, Surgery, Lund University, Lund, SwedenSkåne University Hospital, Lund, SwedenDepartment of Clinical Sciences Lund, Oncology and Therapeutic Pathology, Lund University, Lund, SwedenBackground: Despite improvements in surgical methodologies and perioperative chemo- and radiotherapy, the prognosis for patients with esophageal and gastric cancer remains poor. Hence, there is a great need to identify complementary biomarkers for improved treatment stratification. Tumor-infiltrating immune cells have been shown to impact on outcome in many types of cancer, including gastroesophageal cancer. The aim of this present study was to examine the prognostic value of tumor-infiltrating macrophages in gastroesophageal adenocarcinoma.Methods: The density of CD68+, CD163+, and MARCO+ macrophages was assessed by immunohistochemistry on tissue microarrays with primary tumors from a consecutive, retrospective cohort of 174 patients with treatment-naïve gastroesophageal adenocarcinoma. Total densities and infiltration in tumor nest (TN) were denoted as none/sparse (0), intermediate (1), or high (2). The impact on overall survival (OS) was examined by Kaplan–Meier analysis, log-rank test, and Cox proportional hazards modeling.Results: Increased infiltration of both CD68+ and CD163+, but not MARCO+, macrophages in TN was significantly associated with a stepwise reduced survival. Median OS for patients with none/sparse, intermediate, and high CD68+ TN infiltration was 4.4, 2.6, and 1.0 years, respectively. Median OS for patients with none/sparse, intermediate, and high CD163+ TN infiltration was 4.4, 2.2, and 1.1 years, respectively. High infiltration of CD68+ macrophages remained an independent prognostic factor in adjusted analysis (hazard ratio = 1.61, 95% confidence interval = 1.02–2.55, and p = 0.041).Conclusion: Infiltration of CD68+ and CD163+, but not MARCO+, macrophages is prognostic for OS in gastroesophageal adenocarcinoma. The relevance of this finding in clinical practice remains to be elucidated.https://www.frontiersin.org/articles/10.3389/fonc.2020.534761/fullesophageal cancergastric cancermacrophagesprognosistreatment naïve |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Martin Jeremiasen Martin Jeremiasen David Borg David Borg Charlotta Hedner Maria Svensson Björn Nodin Karin Leandersson Jan Johansson Jan Johansson Karin Jirström |
spellingShingle |
Martin Jeremiasen Martin Jeremiasen David Borg David Borg Charlotta Hedner Maria Svensson Björn Nodin Karin Leandersson Jan Johansson Jan Johansson Karin Jirström Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma Frontiers in Oncology esophageal cancer gastric cancer macrophages prognosis treatment naïve |
author_facet |
Martin Jeremiasen Martin Jeremiasen David Borg David Borg Charlotta Hedner Maria Svensson Björn Nodin Karin Leandersson Jan Johansson Jan Johansson Karin Jirström |
author_sort |
Martin Jeremiasen |
title |
Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma |
title_short |
Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma |
title_full |
Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma |
title_fullStr |
Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma |
title_full_unstemmed |
Tumor-Associated CD68+, CD163+, and MARCO+ Macrophages as Prognostic Biomarkers in Patients With Treatment-Naïve Gastroesophageal Adenocarcinoma |
title_sort |
tumor-associated cd68+, cd163+, and marco+ macrophages as prognostic biomarkers in patients with treatment-naïve gastroesophageal adenocarcinoma |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2020-10-01 |
description |
Background: Despite improvements in surgical methodologies and perioperative chemo- and radiotherapy, the prognosis for patients with esophageal and gastric cancer remains poor. Hence, there is a great need to identify complementary biomarkers for improved treatment stratification. Tumor-infiltrating immune cells have been shown to impact on outcome in many types of cancer, including gastroesophageal cancer. The aim of this present study was to examine the prognostic value of tumor-infiltrating macrophages in gastroesophageal adenocarcinoma.Methods: The density of CD68+, CD163+, and MARCO+ macrophages was assessed by immunohistochemistry on tissue microarrays with primary tumors from a consecutive, retrospective cohort of 174 patients with treatment-naïve gastroesophageal adenocarcinoma. Total densities and infiltration in tumor nest (TN) were denoted as none/sparse (0), intermediate (1), or high (2). The impact on overall survival (OS) was examined by Kaplan–Meier analysis, log-rank test, and Cox proportional hazards modeling.Results: Increased infiltration of both CD68+ and CD163+, but not MARCO+, macrophages in TN was significantly associated with a stepwise reduced survival. Median OS for patients with none/sparse, intermediate, and high CD68+ TN infiltration was 4.4, 2.6, and 1.0 years, respectively. Median OS for patients with none/sparse, intermediate, and high CD163+ TN infiltration was 4.4, 2.2, and 1.1 years, respectively. High infiltration of CD68+ macrophages remained an independent prognostic factor in adjusted analysis (hazard ratio = 1.61, 95% confidence interval = 1.02–2.55, and p = 0.041).Conclusion: Infiltration of CD68+ and CD163+, but not MARCO+, macrophages is prognostic for OS in gastroesophageal adenocarcinoma. The relevance of this finding in clinical practice remains to be elucidated. |
topic |
esophageal cancer gastric cancer macrophages prognosis treatment naïve |
url |
https://www.frontiersin.org/articles/10.3389/fonc.2020.534761/full |
work_keys_str_mv |
AT martinjeremiasen tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma AT martinjeremiasen tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma AT davidborg tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma AT davidborg tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma AT charlottahedner tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma AT mariasvensson tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma AT bjornnodin tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma AT karinleandersson tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma AT janjohansson tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma AT janjohansson tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma AT karinjirstrom tumorassociatedcd68cd163andmarcomacrophagesasprognosticbiomarkersinpatientswithtreatmentnaivegastroesophagealadenocarcinoma |
_version_ |
1724481011860897792 |